The kit is ideally suited to NGS library preparation from a low input, patient-derived sample types, such as nasal swabs
Detecting the presence of undesirable microbes is an integral step in maintaining quality and safety at Coca-Cola
Join us on Thursday, December 17, to learn ways to improve time to result in critical pathways such as sepsis
Join us on Thursday, December 10, to discover how to rapidly diagnose antimicrobial resistance for appropriate therapy
Watch this on-demand webinar to learn how COVID immune responses can be assessed using a novel microfluidic in-solution immunoassay platform
Trends in biomarker discovery methods and novel techniques advancing research, clinical diagnostics and therapeutic development
Watch this on-demand webinar to discover how gel-encapsulated microdroplets can be analyzed by high-throughput droplet sorting for genomic, proteomic, and metabolomic profiling
Dr. Chris Mason shares his extensive research into the SARS-CoV-2 immune response and the similarities experienced by astronauts landing back on Earth
Researchers recommend that targeted nutrition should be urgently explored as a counter-measure to mitochondrial damage
Designed to enrich pathologists' skills in biomarker interpretation and scoring techniques
The assay is developed for use in detection, characterisation, and monitoring of the SARS-CoV-2 virus
From sample prep to downstream analysis, discover the products making a difference for other scientists in your field
Learn how microbiological quality control tests at Coca-Cola ensure consumer safety
All the talks and resources exploring the latest research and methods in the field are now available free and on demand - but for a limited time only
Access SARS-CoV-2 IgG II test is a semi-quantitative assay that measures patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection
Prof. Silke Christiansen describes how she explores the mechanical properties of bone to help better treat osteoporosis and highlights the technological advances enabling new insights
Phase 3 interim analysis including 131 Covid-19 cases indicates that the vaccine is 70.4% effective when combining data from two dosing regimens
